The impact of anti-angiogenic agents on cancer therapy

Marmé, Dieter

doi:10.1007/s00432-003-0488-9

Cited by 25 publications

(14 citation statements)

References 51 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these angiogenic factors, the most potent and specific is vascular endothelial growth factor (VEGF), which not only is crucial for endothelial cell proliferation and blood vessel formation but also induces significant vascular permeability and plays a key role in endothelial cell survival signaling in newly formed vessels (16,17). VEGF has been targeted by a variety of strategies (18)(19)(20)(21), including monoclonal antibodies [e.g., bevacizumab (Avastin) and DC101], inhibitors of endothelial cell receptor-associated tyrosine kinase activity (e.g., SU5474, SU6668, ZD6474, and PTK787/ZK 222584), and antisense. Other approaches, including those targeting basement membrane degradation, endothelial cell migration, endothelial cell proliferation, and tube formation, have also been actively considered (18)(19)(20)(21).…”

Section: Vascular-targeting Approachesmentioning

confidence: 99%

“…VEGF has been targeted by a variety of strategies (18)(19)(20)(21), including monoclonal antibodies [e.g., bevacizumab (Avastin) and DC101], inhibitors of endothelial cell receptor-associated tyrosine kinase activity (e.g., SU5474, SU6668, ZD6474, and PTK787/ZK 222584), and antisense. Other approaches, including those targeting basement membrane degradation, endothelial cell migration, endothelial cell proliferation, and tube formation, have also been actively considered (18)(19)(20)(21). Many of these antiangiogenic therapies are currently under clinical evaluation (18,20,22).…”

Section: Vascular-targeting Approachesmentioning

confidence: 99%

“…Following treatment with VDAs, tumor oxygenation status decreases even further (78,(118)(119)(120)(121)(122). This is clearly associated with the increased necrosis, but studies using 19 F magnetic resonance imaging oximetry suggest that there is a decrease in oxygenation status even in viable tissue (122). Recent measurements of blood flow changes in the tissue that survives VDA treatment support this notion.…”

Section: Pathophysiologic Effects Of Vtasmentioning

confidence: 99%

See 2 more Smart Citations

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

2006

View full text Add to dashboard Cite

A functional vascular supply is critical for the continued growth and development of solid tumors. It also plays a major role in metastatic spread of tumor cells. This importance has led to the concept of targeting the vasculature of the tumor as a form of cancer therapy. Two major types of vasculartargeting agent (VTA) have now emerged: those that prevent the angiogenic development of the neovasculature of the tumor and those that specifically damage the already established tumor vascular supply. When used alone neither approach readily leads to tumor control, and so, for VTAs to be most successful in the clinic they will need to be combined with more conventional therapies. However, by affecting the tumor vascular supply, these VTAs should induce pathophysiologic changes in variables, such as blood flow, pH, and oxygenation. Such changes could have negative or positive influences on the tumor response to more conventional therapies. This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy.

show abstract

Section: Vascular-targeting Approachesmentioning

confidence: 99%

Section: Vascular-targeting Approachesmentioning

confidence: 99%

Section: Pathophysiologic Effects Of Vtasmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

2006

View full text Add to dashboard Cite

show abstract

“…The first approach is to target and inhibit new blood vessel formation in tumors by anti-angiogenic agents (8,(10)(11)(12)(13)(14). The second approach is to target and destroy existing tumor blood vessels by vascular disrupting agents (VDA) (15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Angiogenesis: An update and potential drug approaches (Review)

Abdelrahim¹

2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. The therapeutic potential of targeting tumor endothelium and vascular supply is now widely recognized to treat different diseases. One such disease is cancer; where endothelial cells are actively proliferating to support the tumor growth. Solid tumors cannot grow beyond the size of a few millimeters without inducing the proliferation of endothelium and formation of new blood vessels. Hence it is crucial to search for new agents that selectively block tumor blood supply. These include anti-angiogenic molecules, vascular disrupting agents or endothelial disrupting agents. The antiangiogenic molecules such as monoclonal antibodies and tyrosine kinase inhibitors disrupt endothelial cell survival mechanisms and new blood vessel formation, and vascular disrupting agents for instance ligand-directed and small molecules can be used to disrupt the already existing abnormal vasculature that support tumors by targeting their dysmorphic endothelial cells. The recent advances in this area of research have identified a variety of investigational agents which are currently in clinical development at various stages and some of these candidates are already approved in cancer treatment. This report will review some of the recent developments and most significant advances in this field and outline future challenges and directions.

show abstract

“…Instead, it prevents tumor growth by its insufficient supply with nutrients and oxygen as a result of omitted blood vessel formation [75]. Numerous small molecule inhibitors and neutralizing antibodies targeting regulators of angiogenesis such as VEGF/VEGF receptors are recently under development and in clinical evaluation [108]. For instance, recently the Food and Drug Administration of the U.S.A. approved the anti-VEGF-A-neutralizing antibody Bevacizumab for treatment of stage III-IV colorectal cancer in combination with chemotherapy and for treatment of nonsquamous non-small cell lung cancers, as well as small molecule tyrosine kinase inhibitors for treatment of renal cell cancer (Sorafenib, Sunitinib) and hepatocellular carcinoma (Sorafenib) [109].…”

Section: Therapeutical Interventions Targeting Eph Receptors and Ementioning

confidence: 99%

Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis

Mosch

Reißenweber

Neuber

et al. 2010

Journal of Oncology

101

View full text Add to dashboard Cite

Eph receptors and their ephrin ligands were identified in the late 1980's. Subsequently, they were linked to different physiological and pathophysiological processes like embryonic development, angiogenesis, and tumorigenesis. In this regard, recent work focused on the distribution and effects of Eph receptors and ephrins on tumor cells and tumor microenvironment. The purpose of this review is to outline the role of these molecules in physiological angiogenesis and pathophysiological tumor angiogenesis. Furthermore, novel therapeutical approaches are discussed as Eph receptors and ephrins represent attractive targets for antiangiogenic therapy.

show abstract

The impact of anti-angiogenic agents on cancer therapy

Cited by 25 publications

References 51 publications

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

Angiogenesis: An update and potential drug approaches (Review)

Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis

Contact Info

Product

Resources

About